Cytosorbents
CTSO
$0.82
Share price
1.24%
Change (1 day)
-66.71%
Change (1 year)
Categories
Operating Margin for Cytosorbents (CTSO)
Operating Margin as of April 2024 (TTM): -109.94%
According to Cytosorbents's latest financial reports and stock price the company's current Operating Margin is -109.94%. At the end of 2021 the company had an Operating Margin of -63.07%.
Operating Margin history for Cytosorbents from 2011 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -63.07% | 177.56% |
| 2020 | -22.72% | -74.59% |
| 2019 | -89.42% | 1.57% |
| 2018 | -88.04% | 28.94% |
| 2017 | -68.28% | -54.29% |
| 2016 | -149.37% | -28.36% |
| 2015 | -208.50% | -32.46% |
| 2014 | -308.70% | -50.61% |
| 2013 | -624.99% | -76.64% |
| 2012 | -2,675.43% | -82.39% |
| 2011 | -15,193.88% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 11.27% | -110.25% | 🇺🇸 USA |
 Hologic HOLX | 32.66% | -129.71% | 🇺🇸 USA |
 Meridian Bioscience VIVO | 16.31% | -114.84% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.